Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report is a notification of corporate governance changes rather than a financial results announcement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. No financial data is included in this specific report.
Material Changes
The only material change disclosed is a personnel appointment to the Board of Directors:
- Mr. James Murdoch was appointed as a member of the Remuneration Committee.
- The appointment took effect on October 1, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly limited to the announcement of the board committee change.
Investor Verification Checklist
- Verify the effective date of James Murdoch's appointment to the Remuneration Committee (October 1, 2009).
- Confirm that this filing does not contain financial results for the period ending October 2009.
- Review subsequent filings for the company's actual financial performance and strategic outlook.